[go: up one dir, main page]

WO1996011266A3 - Method for inhibiting smooth muscle cell proliferation and oligonucleotides for use therein - Google Patents

Method for inhibiting smooth muscle cell proliferation and oligonucleotides for use therein Download PDF

Info

Publication number
WO1996011266A3
WO1996011266A3 PCT/US1995/012770 US9512770W WO9611266A3 WO 1996011266 A3 WO1996011266 A3 WO 1996011266A3 US 9512770 W US9512770 W US 9512770W WO 9611266 A3 WO9611266 A3 WO 9611266A3
Authority
WO
WIPO (PCT)
Prior art keywords
oligonucleotides
cell proliferation
smooth muscle
muscle cell
inhibiting smooth
Prior art date
Application number
PCT/US1995/012770
Other languages
French (fr)
Other versions
WO1996011266A2 (en
Inventor
Teresa L Burgess
Catherine L Farrell
Eric F Fisher
Original Assignee
Amgen Inc
Teresa L Burgess
Catherine L Farrell
Eric F Fisher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Teresa L Burgess, Catherine L Farrell, Eric F Fisher filed Critical Amgen Inc
Priority to AU38895/95A priority Critical patent/AU3889595A/en
Publication of WO1996011266A2 publication Critical patent/WO1996011266A2/en
Publication of WO1996011266A3 publication Critical patent/WO1996011266A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides multi-G oligonucleotides that are capable of inhibiting smooth muscle cell proliferation. The multi-G oligonucleotides of the present invention can be used as nucleic acid therapeutic compounds to inhibit smooth muscle cell proliferation in arteries ex vivo, and more particularly against restenosis. The present invention further provides pharmaceutical compositions containing the multi-G oligonucleotides. A method for screening oligonucleotides for their ability to inhibit smooth muscle cell proliferation ex vivo is also provided.
PCT/US1995/012770 1994-10-05 1995-10-03 Method for inhibiting smooth muscle cell proliferation and oligonucleotides for use therein WO1996011266A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU38895/95A AU3889595A (en) 1994-10-05 1995-10-03 Method for inhibiting smooth muscle cell proliferation and oligonucleotides for use therein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31845894A 1994-10-05 1994-10-05
US08/318,458 1994-10-05

Publications (2)

Publication Number Publication Date
WO1996011266A2 WO1996011266A2 (en) 1996-04-18
WO1996011266A3 true WO1996011266A3 (en) 1996-12-12

Family

ID=23238272

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/012770 WO1996011266A2 (en) 1994-10-05 1995-10-03 Method for inhibiting smooth muscle cell proliferation and oligonucleotides for use therein

Country Status (2)

Country Link
AU (1) AU3889595A (en)
WO (1) WO1996011266A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9139554B2 (en) 2008-10-09 2015-09-22 Tekmira Pharmaceuticals Corporation Amino lipids and methods for the delivery of nucleic acids

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2324503T3 (en) 1997-04-10 2009-08-07 Stichting Katholieke Universiteit University Medical Centre Nijmegen PCA3, PCA3 GENES AND METHODS OF USE.
WO2001023550A2 (en) 1999-09-29 2001-04-05 Diagnocure Inc. Pca3 messenger rna species in benign and malignant prostate tissues
ES2427853T3 (en) 2003-02-07 2013-11-04 Diagnocure Inc. Procedure to detect prostate cancer in a sample
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
EP4223299A3 (en) 2007-12-04 2023-08-30 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
JP5749494B2 (en) 2008-01-02 2015-07-15 テクミラ ファーマシューティカルズ コーポレイション Improved compositions and methods for delivery of nucleic acids
NZ588583A (en) 2008-04-15 2012-08-31 Protiva Biotherapeutics Inc Novel lipid formulations for nucleic acid delivery
EP3238738B1 (en) 2008-11-10 2020-09-23 Arbutus Biopharma Corporation Novel lipids and compositions for the delivery of therapeutics
NZ596958A (en) 2009-06-10 2014-04-30 Tekmira Pharmaceuticals Corp Improved lipid formulation
ES2613498T3 (en) 2009-07-01 2017-05-24 Protiva Biotherapeutics Inc. New lipid formulations for the delivery of therapeutic agents to solid tumors
CA2783372C (en) 2009-12-07 2019-07-16 Muthiah Manoharan Compositions for nucleic acid delivery
ES2749426T3 (en) 2009-12-18 2020-03-20 Univ British Columbia Nucleic Acid Administration Methods and Compositions
US20130323269A1 (en) 2010-07-30 2013-12-05 Muthiah Manoharan Methods and compositions for delivery of active agents
WO2012016188A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
AU2012207606B2 (en) 2011-01-11 2017-02-23 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
EP2760477B1 (en) 2011-09-27 2018-08-08 Alnylam Pharmaceuticals, Inc. Di-aliphatic substituted pegylated lipids
BR112014020824B1 (en) 2012-02-24 2022-10-04 Protiva Biotherapeutics Inc LIPID, LIPID PARTICLE AND PHARMACEUTICAL COMPOSITION
AU2014287002A1 (en) 2013-07-11 2016-02-11 Alnylam Pharmaceuticals, Inc. Oligonucleotide-ligand conjugates and process for their preparation
JP7709981B2 (en) 2020-03-17 2025-07-17 ジェネヴァント サイエンシズ ゲーエムベーハー Cationic lipids for lipid nanoparticle delivery of therapeutic agents to hepatic stellate cells
CN117479963A (en) 2020-12-18 2024-01-30 盖纳万科学有限公司 PEG lipids and lipid nanoparticles
US20250243244A1 (en) 2021-03-31 2025-07-31 Entrada Therapeutics, Inc. Cyclic cell penetrating peptides
WO2022240721A1 (en) 2021-05-10 2022-11-17 Entrada Therapeutics, Inc. Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity
MX2023013352A (en) 2021-05-10 2024-01-31 Entrada Therapeutics Inc Compositions and methods for modulating tissue distribution of intracellular therapeutics.
MX2023015509A (en) 2021-06-23 2024-01-22 Entrada Therapeutics Inc Antisense compounds and methods for targeting cug repeats.
WO2023014938A1 (en) 2021-08-05 2023-02-09 Sanegene Bio Usa Inc. 1'-alkyl modified ribose derivatives and methods of use
CN118076619A (en) 2021-09-22 2024-05-24 美国圣因生物股份有限公司 2 '-Alkyl or 3' -alkyl modified ribose derivatives for in vivo delivery of oligonucleotides
CN118076621A (en) 2021-10-05 2024-05-24 美国圣因生物股份有限公司 Polyhydroxylated cyclopentane derivatives and methods of use
JP2025504682A (en) 2022-01-31 2025-02-14 ジェネバント サイエンシズ ゲーエムベーハー Poly(alkyloxazoline)-lipid conjugates and lipid particles containing same
EP4574172A3 (en) 2022-01-31 2025-10-01 Genevant Sciences Gmbh Ionizable cationic lipids for lipid nanoparticles
US20230346819A1 (en) 2022-02-22 2023-11-02 Sanegene Bio Usa Inc. 5'-modified carbocyclic ribonucleotide derivatives and methods of use
KR20250034973A (en) 2022-07-11 2025-03-11 사네진 바이오 유에스에이 인크. Optimized 2'-modified ribose derivatives and methods of use
WO2024229397A1 (en) 2023-05-03 2024-11-07 Sanegene Bio Usa Inc. Lipid-based conjugates for systemic, central nervous system, peripheral nervous system, and ocular delivery
WO2025024523A1 (en) 2023-07-24 2025-01-30 Sanegene Bio Usa Inc. Lipid-based enhancement agent for rna delivery and therapy
WO2025052278A1 (en) 2023-09-05 2025-03-13 Genevant Sciences Gmbh Pyrrolidine based cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells
WO2025133951A1 (en) 2023-12-21 2025-06-26 Genevant Sciences Gmbh Ionizable lipids suitable for lipid nanoparticles

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993001286A2 (en) * 1991-06-28 1993-01-21 Massachusetts Institute Of Technology Localized oligonucleotide therapy
WO1994008053A1 (en) * 1992-09-29 1994-04-14 Isis Pharmaceuticals, Inc. Oligonucleotides having a conserved g4 core sequence

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993001286A2 (en) * 1991-06-28 1993-01-21 Massachusetts Institute Of Technology Localized oligonucleotide therapy
WO1994008053A1 (en) * 1992-09-29 1994-04-14 Isis Pharmaceuticals, Inc. Oligonucleotides having a conserved g4 core sequence

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BURGESS, T. ET AL.: "The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 92, no. 9, 25 April 1995 (1995-04-25), WASHINGTON US, pages 4051 - 4055, XP002015216 *
ECKER, D. ET AL.: "Rational screening of oligonucleotide combinatorial libraries for drug discovery", NUCLEIC ACIDS RESEARCH, vol. 21, no. 8, 25 April 1993 (1993-04-25), OXFORD GB, pages 1853 - 1856, XP002015215 *
FARRELL, C. ET AL.: "The uptake and distribution of phosphorothioate oligonucleotides into vascular smooth muscle cells in vitro and in rabbit arteries", ANTISENSE RESEARCH AND DEVELOPMENT, vol. 5, 1995, US, pages 175 - 183, XP002015217 *
YASWEN, P. ET AL.: "Effects of sequence of thioated oligonucleotides on cultured human mammary epithelial cells", ANTISENSE RESEARCH AND DEVELOPMENT, vol. 3, no. 1, 1993, US, pages 67 - 77, XP002015214 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9139554B2 (en) 2008-10-09 2015-09-22 Tekmira Pharmaceuticals Corporation Amino lipids and methods for the delivery of nucleic acids

Also Published As

Publication number Publication date
AU3889595A (en) 1996-05-02
WO1996011266A2 (en) 1996-04-18

Similar Documents

Publication Publication Date Title
WO1996011266A3 (en) Method for inhibiting smooth muscle cell proliferation and oligonucleotides for use therein
IL109579A0 (en) Bile acid derivatives, processes for their preparation and the use of these compounds as medicaments
HUP0200804A3 (en) The use of pharmaceutical compositions containing 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation
BR9808109A (en) Therapeutic smooth muscle vascular cell inhibitor
HUP0002037A3 (en) Hydroximic acid derivatives, use of them for producing pharmaceutical compositions suitable for inhibiting matrix metalloproteinas and pharmaceutical compositions containing the compounds
CA2359510A1 (en) .omega.-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
HUP0301101A3 (en) Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
HUP0102477A3 (en) Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases and pharmaceutical compositions containing the compounds
HU9502587D0 (en) Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
HU9501963D0 (en) 7-deazapurine modified oligonucleotides
IL125282A (en) Substituted imidazole compounds, process for their preparation, pharmaceutical compositions containing them and use thereof in the preparation of medicaments for treating cytokine mediated diseases
WO1993021942A3 (en) Use of mmp inhibitors
CA2268394A1 (en) New heterocyclylmethyl-substituted pyrazol derivates
EP1420009A3 (en) Novel amino acid derivatives with improved multi-drug resistance activity
NZ333373A (en) Use of amino acid derivatives for preparing compositions with improved multi-drug resistance activity
HUP0203376A3 (en) 5-aryl-1h-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them and their use
IL114586A (en) Droloxifene for use in the treatment of cardiovascular diseases and pharmaceutical compositions comprising same
IL112969A0 (en) Pharmaceutical composition comprising t-cell actiVator for the treatment of cancer
HUP0000678A3 (en) Aminobenzophenones as inhibitors of interleukin and tnf, process for their preparation and pharmaceutical compositions containing the same
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
HUP0200881A2 (en) Renin inhibitors, process for preparation of the compounds, pharmaceutical compositions containing them and their use
HUP0002921A3 (en) Cyanoguanidines as cell proliferation inhibitors, process for producing them and pharmaceutical compositions containing them
GB9804025D0 (en) Orthomolecular medical use of L-citrulline for vasprotection,relaxative smooth muscle tone and cell protection
TJ347B (en) Cryptophicin compounds pharmacentical composition method to inhibit the proliteration of cells and and method to treat neoplasia
HUP9900071A3 (en) Tribenzimidazoles useful as topoisomerase i inhibitors, pharmaceutical compositions containing them and their use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase